277 related articles for article (PubMed ID: 36768616)
1. Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.
Schossig P; Coskun E; Arsenic R; Horst D; Sehouli J; Bergmann E; Andresen N; Sigler C; Busse A; Keller U; Ochsenreither S
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768616
[TBL] [Abstract][Full Text] [Related]
2. Identification and prioritization of tumour-associated antigens for immunotherapeutic and diagnostic capacity in epithelial ovarian cancer: a systematic literature review.
Wiseman L; Cinti N; Guinn BA
Carcinogenesis; 2022 Dec; 43(11):1015-1029. PubMed ID: 36318800
[TBL] [Abstract][Full Text] [Related]
3. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
4. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
6. MAGE-A family serves as poor prognostic markers and potential therapeutic targets for epithelial ovarian cancer patients: a retrospective clinical study.
Sang M; Wu X; Fan X; Lian Y; Sang M
Gynecol Endocrinol; 2017 Jun; 33(6):480-484. PubMed ID: 28277121
[TBL] [Abstract][Full Text] [Related]
7. Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Wei P; Jordan KR; Buhrman JD; Lei J; Deng H; Marrack P; Dai S; Kappler JW; Slansky JE; Yin L
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34074778
[TBL] [Abstract][Full Text] [Related]
8. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
9. Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
Arsenic R; Braicu EI; Letsch A; Dietel M; Sehouli J; Keilholz U; Ochsenreither S
BMC Cancer; 2015 Oct; 15():784. PubMed ID: 26499264
[TBL] [Abstract][Full Text] [Related]
10. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
11. Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.
Genta S; Ghisoni E; Giannone G; Mittica G; Valabrega G
Expert Opin Biol Ther; 2018 Apr; 18(4):359-367. PubMed ID: 29307234
[TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
Garcia-Soto AE; Schreiber T; Strbo N; Ganjei-Azar P; Miao F; Koru-Sengul T; Simpkins F; Nieves-Neira W; Lucci J; Podack ER
Gynecol Oncol; 2017 Jun; 145(3):413-419. PubMed ID: 28392126
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.
Li H; Zhang W; Sun X; Chen J; Li Y; Niu C; Xu B; Zhang Y
Cancer Manag Res; 2018; 10():3433-3450. PubMed ID: 30254487
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
16. Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients.
Kida A; Mizukoshi E; Tamai T; Terashima T; Kitahara M; Arai K; Yamashita T; Fushimi K; Honda M; Kaneko S
Liver Int; 2018 Nov; 38(11):2040-2050. PubMed ID: 29790264
[TBL] [Abstract][Full Text] [Related]
17. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tomita Y; Tsunoda T; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Br J Cancer; 2011 Jan; 104(2):300-7. PubMed ID: 21179034
[TBL] [Abstract][Full Text] [Related]
18. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
Liu S; Matsuzaki J; Wei L; Tsuji T; Battaglia S; Hu Q; Cortes E; Wong L; Yan L; Long M; Miliotto A; Bateman NW; Lele SB; Chodon T; Koya RC; Yao S; Zhu Q; Conrads TP; Wang J; Maxwell GL; Lugade AA; Odunsi K
J Immunother Cancer; 2019 Jun; 7(1):156. PubMed ID: 31221207
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
Spizzo G; Went P; Dirnhofer S; Obrist P; Moch H; Baeuerle PA; Mueller-Holzner E; Marth C; Gastl G; Zeimet AG
Gynecol Oncol; 2006 Nov; 103(2):483-8. PubMed ID: 16678891
[TBL] [Abstract][Full Text] [Related]
20. Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells.
Thelen M; Keller D; Lehmann J; Wennhold K; Weitz H; Bauer E; Gathof B; Brüggemann M; Kotrova M; Quaas A; Mallmann C; Chon SH; Hillmer AM; Bruns C; von Bergwelt-Baildon M; Garcia-Marquez MA; Schlößer HA
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
